<DOC>
	<DOCNO>NCT00813111</DOCNO>
	<brief_summary>The purpose study provide effective postoperative method pain control patient undergoing cosmetic sub-muscular breast augmentation . Appropriate postoperative pain management contribute faster patient mobilization , shorten hospital stay , reduce healthcare cost .</brief_summary>
	<brief_title>Phase 3 Study Local Administration SKY0402 Postoperative Analgesia Subject Undergoing Breast Augmentation</brief_title>
	<detailed_description>This phase 3 study conduct evaluate safety efficacy single local administration 300 mg SKY0402 compare 100 mg conventional , commercially-available bupivacaine HCl ( i.e . Marcaine 0.5 % epinephrine ) administer locally implant pocket breast postoperative analgesia subject undergoing bilateral , cosmetic , sub-muscular , breast augmentation general anesthesia ( endotracheal otherwise ) . A total 600 mg SKY0402 200 mg bupivacaine HCl per subject therefore administer . Post-operative assessment conduct include adverse event serious adverse event monitoring Day 30 .</detailed_description>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>1 . Women great equal 18 year age Screening Visit 2 . Postmenopausal , surgically sterile , willing use acceptable mean contraception least 30 day surgery include follow : hormonal contraceptive ( e.g. , oral , injectable , implantable start least 30 day study administration ) , effective doublebarrier method ( e.g. , condom spermicide ) , intrauterine device , lifestyle personal choice abstinence , nonheterosexual lifestyle , strictly monogamous relationship partner vasectomy . 3 . Scheduled undergo primary , bilateral , cosmetic , submuscular , breast augmentation general anesthesia ( endotracheal otherwise ) 4 . American Society Anesthesiologist ( ASA ) Physical Class 14 5 . Able willing comply study visit procedure , diary entry postoperative day 8 6 . Able speak , read , understand language inform consent form ( ICF ) , study questionnaire , instrument use collect subjectreported outcome , order enable accurate appropriate response pain scale require study assessment 7 . Willing capable provide write informed consent . A subject eligible study meet follow criterion : 1 . Women undergo reconstructive surgery follow mastectomy 2 . Pregnancy , nursing , plan become pregnant study within one month study drug administration . 3 . Use following medication within time specify surgery : 1. longacting opioids within 3 day . 2 . Any opioid medication within 24 hour . 4 . Concurrent painful physical condition concurrent surgery may require analgesic treatment postoperative period pain strictly relate surgical site administer study drug ( e.g. , significant pain joint , chronic neuropathic pain , concurrent abdominal surgery , etc . ) , potential confound postoperative study assessment . 5 . Body weight less 50 kilogram ( 110 pound ) 6 . History hypersensitivity idiosyncratic reaction amidetype local anesthetic , opioid medication , epinephrine , sulfites . 7 . Contraindication epinephrine , concurrent administration ergottype drug , monoamine oxidase ( MAO ) inhibitor antidepressant tryptoline imipramine type , condition production exacerbation tachycardia could provide fatal ( e.g. , poorly control thyrotoxicosis severe heart disease ) pathological condition might aggravate effect epinephrine . 8 . Administration investigational product within 30 day 5 elimination halflives investigational product , whichever longer , prior study drug administration plan administration another investigational product procedure subject 's participation study . 9 . History , suspect , know addiction abuse illicit drug ( ) , prescription medicine ( ) , alcohol within past 2 year . 10 . Uncontrolled anxiety , schizophrenia , psychiatric disorder , opinion investigator , may interfere study assessment compliance protocol . 11 . Significant medical condition laboratory result , opinion Investigator , indicate increase vulnerability study drug procedure , expose subject unreasonable risk result participate clinical trial , : debilitating disease , acute illness , hypotension , partial complete conduction block , impaired cardiac function , untreated hypertension , advance arteriosclerotic heart disease , cerebral vascular insufficiency , preexist abnormal neurological neuromuscular disease ( e.g. , epilepsy , myasthenia gravis ) , advance liver disease , severe renal impairment , advanced diabetes , comorbid condition associate immunocompromised status blood dyscrasia , HIV/AIDS , recent chemotherapy . In addition , subject ineligible receive study drug meet follow criterion surgery : 12 . Any clinically significant event condition uncover surgery ( e.g. , excessive bleeding , acute sepsis ) might render subject medically unstable complicate subject 's postoperative course .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Postsurgical pain</keyword>
	<keyword>Analgesia</keyword>
	<keyword>Breast augmentation</keyword>
</DOC>